Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review
T Fiolet, Y Kherabi, CJ MacDonald, J Ghosn… - Clinical Microbiology …, 2022 - Elsevier
Background Vaccines are critical cost-effective tools to control the coronavirus disease 2019
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
(COVID-19) pandemic. However, the emergence of variants of the severe acute respiratory …
The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022
X Pang, W Xu, Y Liu, H Li, L Chen - European Journal of Medicinal …, 2023 - Elsevier
The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M pro) of …
syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (M pro) of …
Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …
important component of the comprehensive response to the severe acute respiratory …
[HTML][HTML] Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been
deployed globally. We investigated whether antibodies stimulated by mRNA vaccination …
deployed globally. We investigated whether antibodies stimulated by mRNA vaccination …
Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden
P Nordström, M Ballin, A Nordström - The Lancet, 2022 - thelancet.com
Background Vaccine effectiveness against COVID-19 beyond 6 months remains
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
incompletely understood. We aimed to investigate the effectiveness of COVID-19 …
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern …
BNT162b2 vaccine booster and mortality due to Covid-19
Background The emergence of the B. 1.617. 2 (delta) variant of severe acute respiratory
syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine …
syndrome coronavirus 2 and the reduced effectiveness over time of the BNT162b2 vaccine …
Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
KJ Bruxvoort, LS Sy, L Qian, BK Ackerson, Y Luo… - bmj, 2021 - bmj.com
Objectives To evaluate the effectiveness of the mRNA-1273 vaccine against SARS-CoV-2
variants and assess its effectiveness against the delta variant by time since vaccination …
variants and assess its effectiveness against the delta variant by time since vaccination …
Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis
Vaccine protection from symptomatic SARS-CoV-2 infection has been shown to be strongly
correlated with neutralising antibody titres; however, this has not yet been demonstrated for …
correlated with neutralising antibody titres; however, this has not yet been demonstrated for …
[HTML][HTML] Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study …
SV Katikireddi, T Cerqueira-Silva, E Vasileiou… - The Lancet, 2022 - thelancet.com
Background Reports suggest that COVID-19 vaccine effectiveness is decreasing, but
whether this reflects waning or new SARS-CoV-2 variants—especially delta (B. 1.617. 2)—is …
whether this reflects waning or new SARS-CoV-2 variants—especially delta (B. 1.617. 2)—is …